Edwards Lifesciences CorporationEWNYSE
Loading
Revenue Growth Under PressureDecelerating
Percentile Rank36
3Y CAGR-21.8%
5Y CAGR-24.9%
Year-over-Year Change
Year-over-year revenue growth rate
3Y CAGR
-21.8%/yr
vs +45.7%/yr prior
5Y CAGR
-24.9%/yr
Recent acceleration
Acceleration
-67.5pp
Decelerating
Percentile
P36
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.06% |
| Q3 2025 | 1.36% |
| Q2 2025 | 8.46% |
| Q1 2025 | 1.94% |
| Q4 2024 | 2.32% |
| Q3 2024 | -2.27% |
| Q2 2024 | 4.21% |
| Q1 2024 | 5.01% |
| Q4 2023 | 1.85% |
| Q3 2023 | -4.02% |
| Q2 2023 | -11.24% |
| Q1 2023 | 8.25% |
| Q4 2022 | 2.22% |
| Q3 2022 | -4.00% |
| Q2 2022 | 2.44% |
| Q1 2022 | 0.86% |
| Q4 2021 | 1.49% |
| Q3 2021 | -4.78% |
| Q2 2021 | 13.10% |
| Q1 2021 | 2.09% |
| Q4 2020 | 4.45% |
| Q3 2020 | 23.34% |
| Q2 2020 | -18.05% |
| Q1 2020 | -3.87% |
| Q4 2019 | 7.32% |
| Q3 2019 | 0.65% |
| Q2 2019 | 9.46% |
| Q1 2019 | 1.56% |
| Q4 2018 | 7.84% |
| Q3 2018 | -3.93% |
| Q2 2018 | 5.46% |
| Q1 2018 | 0.71% |
| Q4 2017 | 8.16% |
| Q3 2017 | -2.41% |
| Q2 2017 | -4.72% |
| Q1 2017 | 15.08% |
| Q4 2016 | 3.83% |
| Q3 2016 | -2.62% |
| Q2 2016 | 8.89% |
| Q1 2016 | 3.90% |